Patients with severe asthma who are on subcutaneous immunotherapy for allergy treatment do not experience an increased risk for moderate to severe systemic reactions, according to a study published in Annals of Allergy, Asthma & Immunology.
However, further studies are needed to identify factors that may influence rates of severe reactions in this population, Timothy G. Chow, MD, of the division of allergy and immunology in the department of internal medicine at the University of Texas Southwestern Medical Center, and colleagues wrote.
The population included 65,855 patients (mean age, 32.5